Indication
Giant Cell Glioblastoma
12 clinical trials
16 products
4 drugs
Clinical trial
A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type GlioblastomaStatus: Withdrawn, Estimated PCD: 2024-02-01
Product
CYNK-001Clinical trial
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Drug
temozolomideClinical trial
Phase II Clinical Trial of HSV G207 With a Single 5 Gy Radiation Dose in Children With Recurrent High-Grade GliomaStatus: Not yet recruiting, Estimated PCD: 2028-12-02
Product
Biological G207Clinical trial
Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed GlioblastomaStatus: Completed, Estimated PCD: 2023-12-08
Drug
bevacizumabDrug
temozolomideProduct
Microarray AnalysisProduct
DNA methylation analysisClinical trial
A Pilot Study of Utility of 18F-FDOPA-PET for Neurosurgical Planning and Radiotherapy Target Delineation in Glioma Patients: Biopsy Validation of 18F-FDOPA-PET Uptake and Biodistribution in Brain TumorsStatus: Active (not recruiting), Estimated PCD: 2013-11-01
Product
Fluorine F 18 FluorodopaClinical trial
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaStatus: Completed, Estimated PCD: 2022-08-15
Product
LB-100Clinical trial
Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Newly Diagnosed GlioblastomaStatus: Completed, Estimated PCD: 2016-11-16
Product
TMZClinical trial
Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Recurrent GlioblastomaStatus: Completed, Estimated PCD: 2021-06-02
Clinical trial
A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic DrugsStatus: Completed, Estimated PCD: 2014-04-01
Product
CediranibClinical trial
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade GliomasStatus: Completed, Estimated PCD: 2017-03-31
Product
AlisertibClinical trial
Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed GlioblastomaStatus: Completed, Estimated PCD: 2020-10-31
Product
Unpulsed DCsProduct
TdProduct
111In-labeled DCsDrug
VarlilumabProduct
BasiliximabClinical trial
A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant GliomasStatus: Active (not recruiting), Estimated PCD: 2018-10-18
Product
Vorinostat